Format

Send to

Choose Destination
Asian Pac J Cancer Prev. 2012;13(4):1097-104.

Pristimerin inhibits breast cancer cell migration by up- regulating regulator of G protein signaling 4 expression.

Author information

1
Jiangsu Center of Drug Screening, China Pharmaceutical University, Nanjing, China.

Abstract

BACKGROUND/AIM:

Pristimerin isolated from Celastrus and Maytenus spp can inhibit proteasome activity. However, whether pristimerin can modulate cancer metastasis is unknown.

METHODS:

The impacts of pristimerin on the purified and intracellular chymotrypsin proteasomal activity, the levels of regulator of G protein signaling 4 (RGS 4) expression and breast cancer cell lamellipodia formation, and the migration and invasion were determined by enzymatic, Western blot, immunofluorescent, and transwell assays, respectively.

RESULTS:

We found that pristimerin inhibited human chymotrypsin proteasomal activity in MDA-MB-231 cells in a dose-dependent manner. Pristimerin also inhibited breast cancer cell lamellipodia formation, migration, and invasion in vitro by up-regulating RGS4 expression. Thus, knockdown of RGS4 attenuated pristimerin-mediated inhibition of breast cancer cell migration and invasion. Furthermore, pristimerin inhibited growth and invasion of implanted breast tumors in mice.

CONCLUSION:

Pristmerin inhibits proteasomal activity and increases the levels of RGS4, inhibiting the migration and invasion of breast cancer cells.

PMID:
22799288
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Asian Pacific Organization for Cancer Prevention
Loading ...
Support Center